Perspectives on verteporfin therapy combined with intravitreal corticosteroids

Archives of Ophthalmology

Volumn 124, Issue 4, 2006, Pages 561-563

  Schmidt Erfurth, Ursula ^a,c   Michels, Stephan ^a   Augustin, Albert ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; CORTICOSTEROID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; TRIAMCINOLONE ACETATE;

CATARACT; CELL INFILTRATION; COST OF ILLNESS; DRUG MEGADOSE; ENDOPHTHALMITIS; HUMAN; HYPOPYON; HYPOXIA; INTRAOCULAR HYPERTENSION; LASER COAGULATION; MONOTHERAPY; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA SURGERY; SHORT SURVEY; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY;

CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 33645884696     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.124.4.561     Document Type: Short Survey

References (19)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report No. 2. Arch Ophthalmol. 2001;119:198-207.
2. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - VIP Report No. 2. Am J Ophthalmol. 2001;131:541-560.
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfinin Photodynamic Therapy (VIP) Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration - TAP and VIP Report No. 1. Am J Ophthalmol. 2003;136:407-418.
4. Schmidt-Erfurth U, Laqua H, Schloetzer-Schrehard U, Viestenz A, Naumann GOH. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120:835-844.
5. Schmidt-Erfurth U, Schloetzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GOH. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3 and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2003;44:4473-4480.
6. Gollnick SO, Evans SS, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer. 2003;88:1772-1779.
7. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol. 2003;13:159-167.
8. Penfold PL, Madigan MC, Gillies MC, King NJ, Provis JM. Triamcinolone acetonide modulates permeability and intracellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implication for macular degeneration. Clin Exp Immunol. 2000;121:458-465.
9. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol. 2001;119:399-404.
10. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow-up. Aust N Z J Ophthalmol. 1998;26:277-281.
11. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20:244-250.
12. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122:336-340.
13. Jonas JB, Kreissig I, Degenring R. Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2002;240:873-874.
14. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2003;110:1517-1525.
15. Augustin AJ, Schmidt-Erfurth U. Photodynamic therapy with verteporfin combined with intravitreal triamcinolone in occult choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. In press.
16. Augustin AJ, Schmidt-Erfurth U. Photodynamic therapy with verteporfin combined with intravitreal triamcinolone in all lesion types of choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2006;113:14-22.
17. Augustin AJ, Offermann I, Schmidt-Erfurth U. Verteporfin in combination with intravitreal triamcinolone for choroidal neovascularization due to age-related macular degeneration. Presented at: Association of Research in Vision and Ophthalmology; May 1, 2005; Fort Lauderdale, Fla.
18. Kaiser PK, Boyer DS, Mittra RA, et al. Verteporfin photodynamic therapy and intravitreal triamcinolone acetate for choroidal neovascularization due to age-related macular degeneration. Presented at: Association of Research in Vision and Ophthalmology; May 1, 2005; Fort Lauderdale, Fla.
19. Bunse A, Frimpong-Boateng A, Roider J. Photodynamic therapy combined with intravitreal triamcinolone: a comparison of triamcinolone application before and after therapy. Presented at: Association of Research in Vision and Ophthalmology; May 1, 2005; Fort Lauderdale, Fla.